ArticleMolecules (Basel, Switzerland)2025
Systematic Characterization of In Vitro and In Vivo Metabolic Pathways and Identification of Novel Biomarkers of 26 Synthetic Cannabinoids.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Steric-Engineered Thermodynamic Gating: Metastable Assemblies for Chemical-Class Discrimination of Synthetic Cannabinoids.Angewandte Chemie (International ed. in English) · 2026Article
- Study on Phase I Metabolic Processes and Metabolite Biomarker Identification of Synthetic Cannabinoids 5F-ADB-PINACA and 5F-ADBICA in Human Liver Microsomes and Zebrafish Model.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In recent years, the harms and abuse of synthetic cannabinoids (SCs) have attracted extensive attention in society. Their structures have been updated rapidly, which brings great challenges for continuous detection and drug identification. The aim of this study was to elucidate the metabolites of 26 kinds of abused SCs produced in human liver microsomes (HLMs) and rats and to explore the metabolism of indole amides, indazole amides, azaindoles, naphthyl indoles, cyclopropylindoles, naphthyl benzimidazole, and naphthyl pyrrole SCs in vivo and in vitro. Human liver microsomes were incubated with SCs to simulate human metabolic processes, and the in vitro metabolic model of liver microsomes was established. After the SD rats were randomized into groups, 26 kinds of SCs and normal saline were injected respectively to establish the rat model after exposure. The metabolites were identified one by one using a UHPLC-Q-Exactive Orbitrap MS method to explore the metabolic law. A total of 609 metabolites were identified, involving 30 metabolic pathways. The metabolism of SCs was summarized from the parent nuclear group, the head group, the linking group, and the tail side chain, and the mass spectral fragmentation pattern of the metabolites was analyzed in order to provide reference for the examination and identification of SCs-related cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.